血管生成素样蛋白在非酒精性脂肪性肝病发展中的作用

郑培玉; 安秀琴; 刘近春

doi:10.3969/j.issn.1001-5256.2021.11.042

血管生成素样蛋白在非酒精性脂肪性肝病发展中的作用

DOI: 10.3969/j.issn.1001-5256.2021.11.042

1.
山西医科大学研究生院，太原 030001
2.
山西医科大学第一医院消化内科，太原 030001

基金项目:

山西省科技成果转化引导专项项目 (201904D131030)

详细信息

通信作者:
刘近春，zxr610624@163.com

中图分类号: R575.5
计量
- 文章访问数: 525
- HTML全文浏览量: 265
- PDF下载量: 37
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-14
- 录用日期: 2021-04-19
- 出版日期: 2021-11-20

Role of angiopoietin-like proteins in the development of nonalcoholic fatty liver disease

1.
Graduate School of Shanxi Medical University, Taiyuan 030001, China
2.
Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Scientific and Technological Achievements Transformation Guidance Special of Shanxi Province, China (201904D131030)

摘要

摘要: 血管生成素样因子(ANGPTL)是近年来发现的一类与血管生成素在组成上具有同源性，并具有调节血管生成作用的分泌性糖蛋白家族。近年来，越来越多的研究表明ANGPTL在糖脂代谢、炎症和肿瘤中具有重要的作用。众所周知，非酒精性脂肪性肝病(NAFLD)及其疾病谱与代谢、炎症、肿瘤密切相关，现就ANGPTL在NAFLD中的作用作一综述，以期为临床防治NAFLD提供新的思路。
- 非酒精性脂肪性肝病 /
- 血管生成素类 /
- 脂类代谢
Abstract: Angiopoietin-like proteins (ANGPTLs) are a family of secretory glycoproteins recently found to be constitutionally homologous with angiogenin and play a role in the regulation of angiogenesis. In recent years, more and more studies have shown that ANGPTLs play an important role in glucose and lipid metabolism, inflammation, and tumor. As we all know, nonalcoholic fatty liver disease and its disease spectrum are closely associated with metabolism, inflammation, and tumor. This article reviews the role of ANGPTLs in various diseases associated with nonalcoholic fatty liver disease, in order to provide new ideas for the prevention and treatment of nonalcoholic fatty liver disease in clinical practice.
- Non-alcoholic Fatty Liver Disease /
- Angiopoietins /
- Ipid Metabolism

HTML全文

图 1 ANGPTL在NAFLD中的作用机制示意图

下载: 全尺寸图片幻灯片

参考文献(44)

[1]	SUO YH, LIU JC. Research advances in the treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2018, 34(10): 2232-2236. DOI: 10.3969/j.issn.1001-5256.2018.10.038. 索宇鸿, 刘近春. 非酒精性脂肪性肝病的治疗进展[J]. 临床肝胆病杂志, 2018, 34(10): 2232-2236. DOI: 10.3969/j.issn.1001-5256.2018.10.038.
[2]	SASAKI Y, OHTA M, DESAI D, et al. Angiopoietin like protein 2 (ANGPTL2) promotes adipose tissue macrophage and T lymphocyte accumulation and leads to insulin resistance[J]. PLoS One, 2015, 10(7): e0131176. DOI: 10.1371/journal.pone.0131176.
[3]	HORIO E, KADOMATSU T, MIYATA K, et al. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression[J]. Arterioscler Thromb Vasc Biol, 2014, 34(4): 790-800. DOI: 10.1161/ATVBAHA.113.303116.
[4]	DIJK W, KERSTEN S. Regulation of lipid metabolism by angiopoietin-like proteins[J]. Curr Opin Lipidol, 2016, 27(3): 249-256. DOI: 10.1097/MOL.0000000000000290.
[5]	KERSTEN S. Angiopoietin-like 3 in lipoprotein metabolism[J]. Nat Rev Endocrinol, 2017, 13(12): 731-739. DOI: 10.1038/nrendo.2017.119.
[6]	BARCHETTA I, CIMINI FA, CHIAPPETTA C, et al. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity[J]. Liver Int, 2020, 40(9): 2139-2147. DOI: 10.1111/liv.14554.
[7]	YANG LY, WANG Y, XU YC, et al. Effect of angiopoietin-like 4 in the diagnosis of nonalcoholic fatty liver[J]. J Capit Med Univ, 2020, 41(1): 31-34. DOI: 10.3969/j.issn.1006-7795.2020.01.006. 杨龙艳, 王岩, 许月超, 等. 血管生成素样蛋白4在非酒精性脂肪肝诊断中的应用效果分析[J]. 首都医科大学学报, 2020, 41(1): 31-34. DOI: 10.3969/j.issn.1006-7795.2020.01.006.
[8]	ALGHANIM G, QADDOUMI MG, ALHASAWI N, et al. Higher levels of ANGPTL5 in the circulation of subjects with obesity and type 2 diabetes are associated with insulin resistance[J]. Front Endocrinol (Lausanne), 2019, 10: 495. DOI: 10.3389/fendo.2019.00495.
[9]	KIM MJ, NAMKUNG J, CHANG JS, et al. Leptin regulates the expression of angiopoietin-like 6[J]. Biochem Biophys Res Commun, 2018, 502(3): 397-402. DOI: 10.1016/j.bbrc.2018.05.180.
[10]	LEE YH, LEE SG, LEE CJ, et al. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: Animal and human studies[J]. Sci Rep, 2016, 6: 24013. DOI: 10.1038/srep24013.
[11]	HONG BS, LIU J, ZHENG J, et al. Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients[J]. J Diabetes Investig, 2018, 9(4): 952-958. DOI: 10.1111/jdi.12792.
[12]	GARCÍA-MONZÓN C, PETROV PD, REY E, et al. Angiopoietin-like protein 8 is a novel vitamin D receptor target gene involved in nonalcoholic fatty liver pathogenesis[J]. Am J Pathol, 2018, 188(12): 2800-2810. DOI: 10.1016/j.ajpath.2018.07.028.
[13]	BARCHETTA I, CIMINI FA, CHIAPPETTA C, et al. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity[J]. Liver Int, 2020, 40(9): 2139-2147. DOI: 10.1111/liv.14554.
[14]	JAHN D, DORBATH D, SCHILLING AK, et al. Intestinal vitamin D receptor modulates lipid metabolism, adipose tissue inflammation and liver steatosis in obese mice[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6): 1567-1578. DOI: 10.1016/j.bbadis.2019.03.007.
[15]	MEHTA N, QAMAR A, QU L, et al. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5): 1057-1063. DOI: 10.1161/ATVBAHA.113.302802.
[16]	TIKKA A, JAUHIAINEN M. The role of ANGPTL3 in controlling lipoprotein metabolism[J]. Endocrine, 2016, 52(2): 187-193. DOI: 10.1007/s12020-015-0838-9.
[17]	GRAHAM MJ, LEE RG, BRANDT TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides[J]. N Engl J Med, 2017, 377(3): 222-232. DOI: 10.1056/NEJMoa1701329.
[18]	WANG Y, LIU LM, WEI L, et al. Angiopoietin-like protein 4 improves glucose tolerance and insulin resistance but induces liver steatosis in high-fat-diet mice[J]. Mol Med Rep, 2016, 14(4): 3293-3300. DOI: 10.3892/mmr.2016.5637.
[19]	LA PAGLIA L, LISTÌ A, CARUSO S, et al. Potential role of ANGPTL4 in the cross talk between metabolism and cancer through PPAR signaling pathway[J]. PPAR Res, 2017, 2017: 8187235. DOI: 10.1155/2017/8187235.
[20]	ZHANG R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking[J]. Open Biol, 2016, 6(4): 150272. DOI: 10.1098/rsob.150272.
[21]	KITAZAWA M, NAGANO M, MASUMOTO KH, et al. Angiopoietin-like 2, a circadian gene, improves type 2 diabetes through potentiation of insulin sensitivity in mice adipocytes[J]. Endocrinology, 2011, 152(7): 2558-2567. DOI: 10.1210/en.2010-1407.
[22]	WANG Y, MCNUTT MC, BANFI S, et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis[J]. Proc Natl Acad Sci U S A, 2015, 112(37): 11630-11635. DOI: 10.1073/pnas.1515374112.
[23]	KANG SG, YI HS, CHOI MJ, et al. ANGPTL6 expression is coupled with mitochondrial OXPHOS function to regulate adipose FGF21[J]. J Endocrinol, 2017, 233(1): 105-118. DOI: 10.1530/JOE-16-0549.
[24]	RONG GUO X, LI WANG X, CHEN Y, et al. ANGPTL8/betatrophin alleviates insulin resistance via the Akt-GSK3β or Akt-FoxO1 pathway in HepG2 cells[J]. Exp Cell Res, 2016, 345(2): 158-167. DOI: 10.1016/j.yexcr.2015.09.012.
[25]	ZHANG Z, WU H, DAI L, et al. ANGPTL8 enhances insulin sensitivity by directly activating insulin-mediated AKT phosphorylation[J]. Gene, 2020, 749: 144707. DOI: 10.1016/j.gene.2020.144707.
[26]	COX AR, BARRANDON O, CAI EP, et al. Resolving discrepant findings on ANGPTL8 in β-cell proliferation: A collaborative approach to resolving the betatrophin controversy[J]. PLoS One, 2016, 11(7): e0159276. DOI: 10.1371/journal.pone.0159276.
[27]	SAHARINEN P, EKLUND L, ALITALO K. Therapeutic targeting of the angiopoietin-TIE pathway[J]. Nat Rev Drug Discov, 2017, 16(9): 635-661. DOI: 10.1038/nrd.2016.278.
[28]	FU X, CHEN H, HAN S. C16 peptide and angiopoietin-1 protect against LPS-induced BV-2 microglial cell inflammation[J]. Life Sci, 2020, 256: 117894. DOI: 10.1016/j.lfs.2020.117894.
[29]	CHANDEL S, SATHIS A, DHAR M, et al. Hyperinsulinemia promotes endothelial inflammation via increased expression and release of Angiopoietin-2[J]. Atherosclerosis, 2020, 307: 1-10. DOI: 10.1016/j.atherosclerosis.2020.06.016.
[30]	KADOMATSU T, ENDO M, MIYATA K, et al. Diverse roles of ANGPTL2 in physiology and pathophysiology[J]. Trends Endocrinol Metab, 2014, 25(5): 245-254. DOI: 10.1016/j.tem.2014.03.012.
[31]	LU Z, HE B, CHEN Z, et al. Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway[J]. BMC Immunol, 2020, 21(1): 28. DOI: 10.1186/s12865-020-00358-9.
[32]	HESS AL, CARAYOL J, BLÆDEL T, et al. Analysis of circulating angiopoietin-like protein 3 and genetic variants in lipid metabolism and liver health: The DiOGenes study[J]. Genes Nutr, 2018, 13: 7. DOI: 10.1186/s12263-018-0597-3.
[33]	EL-SHAL AS, ZIDAN HE, RASHAD NM, et al. Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma[J]. Cytokine, 2017, 96: 75-86. DOI: 10.1016/j.cyto.2017.03.006.
[34]	ZHU P, GOH YY, CHIN HF, et al. Angiopoietin-like 4: A decade of research[J]. Biosci Rep, 2012, 32(3): 211-219. DOI: 10.1042/BSR20110102.
[35]	CINKAJZLOVA A, LACINOVA Z, KLOUCKOVA J, et al. Angiopoietin-like protein 6 in patients with obesity, type 2 diabetes mellitus, and anorexia nervosa: The influence of very low-calorie diet, bariatric surgery, and partial realimentation[J]. Endocr Res, 2017, 42(1): 22-30. DOI: 10.3109/07435800.2016.1169544.
[36]	POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Leptin in nonalcoholic fatty liver disease: A narrative review[J]. Metabolism, 2015, 64(1): 60-78. DOI: 10.1016/j.metabol.2014.10.012.
[37]	POLYZOS SA, ARONIS KN, KOUNTOURAS J, et al. Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Diabetologia, 2016, 59(1): 30-43. DOI: 10.1007/s00125-015-3769-3.
[38]	REN G, KIM JY, SMAS CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism[J]. Am J Physiol Endocrinol Metab, 2012, 303(3): E334-351. DOI: 10.1152/ajpendo.00084.2012.
[39]	CHEN HA, KUO TC, TSENG CF, et al. Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma[J]. Hepatology, 2016, 64(5): 1637-1651. DOI: 10.1002/hep.28773.
[40]	GAO L, GE C, FANG T, et al. ANGPTL2 promotes tumor metastasis in hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2015, 30(2): 396-404. DOI: 10.1111/jgh.12702.
[41]	YU H, ZHANG H, LI D, et al. Effects of ANGPTL3 antisense oligodeoxynucleotides transfection on the cell growths and invasion of human hepatocellular carcinoma cells[J]. Hepatogastroenterology, 2011, 58(110-111): 1742-1746. DOI: 10.5754/hge10647.
[42]	KOYAMA T, OGAWARA K, KASAMATSU A, et al. ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer[J]. Cancer Med, 2015, 4(5): 759-769. DOI: 10.1002/cam4.418.
[43]	HAN S, XU W, WANG Z, et al. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment[J]. Oncotarget, 2016, 7(25): 37773-37789. DOI: 10.18632/oncotarget.9329.
[44]	PARRI M, PIETROVITO L, GRANDI A, et al. Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer[J]. Angiogenesis, 2014, 17(4): 881-896. DOI: 10.1007/s10456-014-9435-4.